Omalizumab therapy in atopic dermatitis: Depletion of IgE does not improve the clinical course - A randomized, placebo-controlled and double blind pilot study;Omalizumab-Therapie atopischer Dermatitis: IgE-Depletion führt nicht zur klinischen Besserung - Eine randomisierte, placebo-kontrollierte, doppelblinde Pilotstudie

JDDG - Journal of the German Society of Dermatology

Volumn 8, Issue 12, 2010, Pages 990-998

  Heil, Peter Maximilian ^a   Maurer, Dieter ^a   Klein, Brigitte ^a   Hultsch, Thomas ^b,c   Stingl, Georg ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

anti IgE; atopic dermatitis; IgE depletion; IgE receptor; Omalizumab; surface bound IgE

Indexed keywords

ALLERGEN; FC RECEPTOR; IMMUNOGLOBULIN E; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN; OMALIZUMAB; PLACEBO;

ADULT; ARTICLE; ATOPIC DERMATITIS; BLEPHARITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEADACHE; HEMATOMA; HERPES LABIALIS; HUMAN; HUMAN CELL; HYPERSENSITIVITY; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO STUDY; INJECTION SITE REACTION; MALE; MIGRAINE; MUSCLE STRAIN; PATCH TEST; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRICK TEST; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SORE THROAT; TONSILLITIS; VERTIGO;

EID: 78650201074     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2010.07497.x     Document Type: Article

References (37)

1. Klubal R, Osterhoff B, Wang B, Kinet JP, Maurer D, Stingl G,. The high-affinity receptor for IgE is the predominant IgE-binding structure in lesional skin of atopic dermatitis patients. J Invest Dermatol 1997; 108: 336-42.
2. Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G,. The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol 1995; 154: 6285-90.
3. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB,. Omalizumab rapidly decreases nasal allergic response and Fc epsilon RI on basophils. J Allergy Clin Immunol 2004; 113: 297-302.
4. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S,. Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol 2004; 114: 527-30.
5. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB,. Omalizumab treatment downregulates dendritic cell FcεRI expression. J Allergy Clin Immunol 2003; 112: 1147-54.
6. Poole JA, Matangkasombut P, Rosenwasser LJ,. Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol Suppl 2005; 115: S376-85.
7. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C,. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 459-65.
8. Rafi A, Do LT, Katz R, Sheinkopf LE, Simons CW, Klaustermeyer W,. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 2010; 31: 76-83.
9. Schulze J, Rose M, Zielen S,. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007; 62: 963-4.
10. Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou TT, Ying S, Kay AB,. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 2005; 116: 558-64.
11. Hanifin JM, Rajka G,. Diagnostic features of atopic dermatitis. Acta Derm Venerol Suppl 1980; 92: 44-47.
12. Frigeri L, Liu FT,. Surface expression of functional IgE binding protein, an en-dogenous lectin, on mast cells and macrophages. J Immunol 1992; 148: 861-867.
13. Wang B, Rieger A, Kilgus O, Ochiai K, Maurer D, Födinger D, Kinet JP, Stingl G,. Epidermal Langerhans cells from normal human skin bind monomeric IgE via Fc epsilon RI. J Exp Med 1992; 175: 1353-65.
14. Beck L, Saini S,. Wanted: a study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis. J Am Acad Dermatol 2006; 55: 540-41.
15. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E, Gustafssohn H, Sandström T, Rak S,. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002; 110: 68-71.
16. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV,. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583-93.
17. Kraft S, Kinet JP,. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007; 7: 365-378.
18. Pacheco-Lopez G, Engler H, Niemi M-B, Schedlowski M,. Expectations and associations that heal: Immunomo-dulatory placebo effects and its neurobiology. Brain Behav and Immun 2006; 20: 430-46.
19. Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte, Cantu-Gonzales G, Milgrom H, Boguniewicz M, Cooper KD,. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993; 28: 189-197.
20. Gauci M, Husband AJ, Saxarra H, King MG,. Pavlovian conditioning of nasal tryptase release in human subjects with allergic rhinitis. Physiol Behav 1994; 55: 823-5.
21. Krathen RA, Hsu S,. Failure of omalizu-mab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005; 53: 338-40.
22. Corren J, Shapiro G, Reimann J, Deniz Y, Wong D, Adelman D, Togias A,. Allergen skin tests and free IgE levels during reduction and cessation of oma-lizumab therapy. J Allergy Clin Immunol 2008; 121: 506-11.
23. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB,. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008; 29: 530-37.
24. Incorvaia C, Pravettoni C, Mauro M, Yacoub MR, Tarantini F, Riario-Sforza GG,. Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 2008; 69: 78-80.
25. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S, Andres C, Schnopp C, Ring J, Hein R, Ollert M, Mempel M,. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120: 1223-1225.
26. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I,. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006; 55: 168-170.
27. Forman SB, Garrett AB,. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immuno-globulin E receptor, Fcepsilon RI. Cutis 2007; 80: 38-40.
28. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ,. Treatment of recalcitrant atopic dermatitis with omalizu-mab. J Am Acad Dermatol 2006; 54: 68-72.
29. Boguniewicz M, Schmid-Grendelmeier P, Leung DY,. Atopic dermatitis. J Allergy Clin Immunol 2006; 118: 40-43.
30. Andres C, Belloni B, Mempel M, Ring J,. Omalizumab for Patients with Severe and Therapy-Refractory Atopic Eczema? Curr Allergy Asthma Rep 2008; 8: 179-80.
31. Schmitt J, Schäkel K,. Omalizumab als therapeutische Alternative beim atopischen Ekzem. Hautarzt 2007; 58: 128-132.
32. Caruso C, Gaeta F, Valluzzi RL, Romano A,. Omalizumab efficacy in a girl with atopic eczema. Allergy 2010; 65: 278-279.
33. Leung DY, Bieber T,. Atopic dermatitis. Lancet 2003; 361: 151-60. (Pubitemid 36092023)
34. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y,. Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis. J Invest Dermatol 2008; 128: 2625-2630.
35. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, Schneider L, Beck LA, Barnes KC, Leung DY,. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007; 120: 150-55.
36. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY,. Endogenous antimicrobial peptides and skin infections in ato-pic dermatitis. N Engl J Med 2002; 347: 1151-60.
37. Noga O, Hanf G, Kunkel G,. Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab. Int Arch Allergy Immunol 2003; 131: 46-52.